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Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear [1] [2] [3] [4] [5] [6] . Metformin lowers blood glucose levels by inhibiting hepatic glucose production (HGP), an effect originally postulated to be due to a hepatic AMP-activated protein kinase (AMPK)-dependent mechanism 5, 6 . However, studies have questioned the contribution of hepatic AMPK to the effects of metformin on lowering hyperglycemia 1, 3, 4 , and a gut-brain-liver axis that mediates intestinal nutrient-and hormone-induced lowering of HGP has been identified 7 . Thus, it is possible that metformin affects HGP through this inter-organ crosstalk. Here we show that intraduodenal infusion of metformin for 50 min activated duodenal mucosal Ampk and lowered HGP in a rat 3 d high fat diet (HFD)-induced model of insulin resistance. Inhibition of duodenal Ampk negated the HGPlowering effect of intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)-protein kinase A (Pka) signaling and a neuronal-mediated gut-brain-liver pathway were required for metformin to lower HGP. Preabsorptive metformin also lowered HGP in rat models of 28 d HFD-induced obesity and insulin resistance and nicotinamide (NA)-streptozotocin (STZ)-HFD-induced type 2 diabetes. In an unclamped setting, inhibition of duodenal Ampk reduced the glucose-lowering effects of a bolus metformin treatment in rat models of diabetes. These findings show that, in rat models of both obesity and diabetes, metformin activates a previously unappreciated duodenal Ampkdependent pathway to lower HGP and plasma glucose levels.
Diabetes is characterized by disrupted glucose homeostasis due partly to increased hepatic glucose production (HGP) 8 . The biguanide metformin lowers plasma glucose levels by reducing HGP [9] [10] [11] , in addition to improving insulin sensitivity 12 , in diabetic humans and rodent models of diabetes. It was originally postulated that metformin decreases HGP by inhibiting mitochondrial complex I 13 , which results in an elevation of AMP levels and activation of AMPK through liver kinase B1 (LKB1)-dependent phosphorylation of AMPK 5, 14 . Validation of this mechanism includes data showing that chemical inhibition of AMPK negates the ability of metformin to inhibit HGP in hepatocytes 6 , and hepatic knockout of Stk11 (encoding Lkb1) abolishes the ability of chronic metformin to activate hepatic Ampk and lower plasma glucose levels in diabetic rodents 5 . However, that the glucose-lowering effect of acute oral metformin is intact in mice that lack Ampk in the liver 1 , and that only high doses of metformin inhibit hepatic complex I respiration 3 , challenge the originally postulated underlying mechanism. Specifically, recent studies report that metformin inhibits HGP through a hepatic AMPK-independent mechanism, either by negating the ability of glucagon to increase hepatic cAMP levels and stimulate HGP 4 or by decreasing hepatic mitochondrial redox states and lowering the conversion of metabolites to glucose 3 . Additionally, chronic metformin treatment reduces hepatic lipogenesis and subsequent lipid accumulation to improve insulin sensitivity 2 . These findings indicate that the underlying mechanisms responsible for the HGP-and glucose-lowering effects of metformin in type 2 diabetes remain unclear.
The gastrointestinal tract triggers negative feedback systems to maintain glucose homeostasis 7 . Specifically, duodenal lipids activate a duodenal cholecystokinin (CCK)-1 receptor-and gutbrain-liver-dependent neuronal network to lower HGP in healthy rodents, and jejunal nutrient-and leptin-sensing lower HGP in both healthy and diabetic rodents [15] [16] [17] [18] . The pharmacological nature of such sensory mechanisms, however, is completely unknown. To this end, some early evidence indicates a potential role of the gut in mediating the effects of metformin. For example, intraduodenal (as compared to intraportal and intravenous) administration of metformin leads to the greatest drop of plasma glucose levels 19 , and chronic metformin administration increases Glp-1 secretion and alters the microbiota profile [20] [21] [22] . Furthermore, Ampk is expressed in the intestine, and metformin increases intestinal Ampk activity 23 . We hypothesize that preabsorptive metformin activates both a duodenal Ampk-dependent mechanism and a neuronal relay to lower HGP and plasma glucose levels in individuals with diabetes or obesity (Fig. 1a) .
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats
We first examined the effects of intraduodenal metformin infusion on HGP in 3 d hyperphagic HFD (lard-oil enriched; Supplementary Table 1)-induced insulin-resistant rats (the experimental model is outlined in Fig. 1b , and the insulin-resistance phenotype was confirmed (data not shown)). Given that metformin lowers HGP independently of insulin action 1, 4 , we chose to assess changes in glucose metabolism using the pancreatic (basal insulin)-euglycemic clamp to establish our studies in a non-insulin stimulated environment. When metformin (200 mg kg −1 ) was infused into the duodenal lumen of rats for only 50 min, the glucose infusion rate required to maintain euglycemia was higher than in saline-infused control rats (Fig. 1c) , and HGP was reduced from its basal level in metformin-treated but not saline-infused controls ( Fig. 1d and Supplementary Fig. 1a ). Glucose uptake (Fig. 1e) and plasma insulin and glucose levels remained comparable among groups (Supplementary Table 2) . A portal vein infusion of the same dose of metformin for 50 min did not raise the glucose infusion rate (Fig. 1c) or lower HGP compared to saline infusion ( Fig. 1d and Supplementary Fig. 1a) , indicating that the HGPlowering effect of intraduodenal metformin infusion is preabsorptive.
It is possible that differences in experimental design and conditions (such as chronic versus acute metformin treatment, slow constant infusion versus bolus injection of metformin, pancreatic clamp versus unclamp studies and various rodent fasting periods) between our study and previous studies [1] [2] [3] [4] [5] may have accounted for the observed lack of a direct hepatic effect of metformin when delivered by portal infusion. Nonetheless, to strengthen our claim about the preabsorptive effects of metformin, we repeated the infusion-clamp studies using a lower and clinically relevant dose of metformin. Intraduodenal infusion of metformin at 50 mg kg −1 resulted in a higher glucose infusion rate (Supplementary Fig. 1b ) and lower HGP ( Supplementary  Fig. 1c,d ) with no difference in glucose uptake (Supplementary Fig. 1e) , as compared to saline infusion. Thus, intraduodenal metformin administration activates preabsorptive mechanisms to lower HGP.
We found that the duodenal mucosa of metformin-treated rats had a higher ratio of phosphorylated Ampk (pAmpk) to total Ampk (tAmpk) (Fig. 1f) and higher Ampk activity (Fig. 1g) than that of saline-treated rats. We then investigated whether duodenal Ampk activation per se lowers HGP by using an Ampk activator, A769662. The glucose infusion rate was higher (Supplementary Fig. 1b) and HGP was lower following intraduodenal infusion of A769662 (3 mg kg −1 ) compared to those in saline-infused controls ( Supplementary Fig. 1c,d ), but glucose uptake was unchanged between all groups (Supplementary Fig. 1e ). Furthermore, we co-infused metformin with compound C, an Ampk inhibitor. Intraduodenal compound C alone did not affect glucose metabolism (compared to intraduodenal saline), but co-infusion with metformin fully negated the higher glucose infusion rate (Supplementary Fig. 1f ) and lower HGP (Supplementary Fig. 1g,h ) observed with metformin infusion alone, without changing glucose uptake between groups (Supplementary Fig. 1i) .
However, as compound C is a relatively poor specific inhibitor of AMPK 24 , we alternatively confirmed the role of duodenal AMPK by utilizing an adenovirus encoding the dominant negative-acting Ampk-mutated protein (Ad-dn-Ampk) (Fig. 2a) . We first confirmed the functionality of this virus by using HEK293 human embryonic kidney cells infected with either Ad-dn-Ampk or adenovirus encoding green fluorescent protein (Ad-GFP; control), and assessed protein expression of acetyl-CoA carboxylase (ACC), a direct downstream target of AMPK 2 . Among the cells infected with Ad-GFP, those treated with metformin (10 mM) for 6 h (as originally described in ref. 25 ) exhibited a higher ratio of phosphorylated ACC (pACC) to total ACC than those treated with saline, and this effect was negated in Ad-dn-Ampk cells treated with metformin (Supplementary Fig. 2a) . Next, using a procedure that maximized duodenal infection without infecting the jejunum, ileum or liver, we injected either Ad-dn-Ampk or Ad-GFP into a 5 cm ligated section of the duodenum of HFD-fed rats. Intraduodenal infusion of metformin resulted in a higher glucose infusion rate (Fig. 2b) and lower HGP ( Fig. 2c and Supplementary  Fig. 2b ) without affecting glucose uptake (Supplementary Fig. 2c ) in Ad-GFP-injected control rats as compared to rats given a saline infusion, but we found no difference in the glucose infusion rate, HPG or glucose uptake between Ad-dn-Ampk-injected rats infused with metformin as compared to saline (Fig. 2b,c and Supplementary  Fig. 2b,c) . Following metformin treatment, Ampk activity in the duodenal mucosa was lower in Ad-dn-Ampk-injected rats than in Ad-GFP-injected rats ( Supplementary Fig. 2d ). These data collectively indicate that duodenal AMPK activation is required for preabsorptive metformin to lower HGP. We next chose to specifically examine the roles of Cck and Glp-1, as duodenal Cck signaling triggers a gut-brain-liver axis to lower HGP 15 and metformin stimulates Glp-1 release 20 . Thus, we infused metformin intraduodenally with either the Cck-1 receptor antagonist MK-329 or the Glp-1 receptor (Glp1r) antagonist exendin-9 (Ex9) (Fig. 2a) . HFD-fed rats co-infused with metformin and MK-329 had a higher glucose infusion rate (Fig. 2d) and lower HGP (Fig. 2e and  Supplementary Fig. 2e ) than saline-infused rats, but co-infusion with Ex9 reversed the ability of metformin to alter glucose metabolism (Fig. 2d,e and Supplementary Fig. 2e,f) . Ex9 or MK-329 alone had no effect on glucose metabolism (Fig. 2d,e and Supplementary  Fig. 2e,f) . Thus, intestinal Glp-1 signaling, but not Cck-1 signaling, is required for metformin's action.
Given that Cck lowers HGP via Cck-1-receptor activation of Pka signaling on vagal afferents 26 , Glp1rs are localized on vagal afferents innervating the small intestine 27 , and Glp1r activation induces Pka signaling 28 , we examined whether the effect of metformin requires Pka signaling (Fig. 2a) . Even though infusion of the Pka chemical inhibitor Rp-CAMPS by itself did not alter the glucose infusion rate (Fig. 2d) , HGP ( Fig. 2e and Supplementary Fig. 2e ) or glucose uptake (Supplementary Fig. 2f ) compared to saline infusion, intraduodenal co-infusion of metformin and Rp-CAMPS abolished the higher glucose infusion rate (Fig. 2d) and lower HGP ( Fig. 2e and Supplementary Fig. 2e ) observed with metformin infusion alone. Duodenal Pka activity was higher following intraduodenal metformin infusion than following saline infusion, and this activation was abolished by co-infusion with Ex9 (Fig. 2f) , indicating that Glp1r activation is necessary for metformin to increase Pka activity. These results demonstrate that metformin requires a duodenal Ampk-Glp1r-Pka signaling pathway to lower HGP.
We next examined whether a gut-brain-liver axis mediates the effect of metformin using three different techniques: intraduodenal infusion of tetracaine, infusion of the NMDA receptor blocker MK-801 into the nucleus of the solitary tract (NTS) and hepatic vagotomy (Fig. 3a,b) . In 3 d HFD-fed rats, we first administered, with or without metformin, the local anesthetic tetracaine, in order to inhibit the neurotransmission of afferent fibers innervating the duodenum. Tetracaine infusion alone did not affect glucose metabolism compared to saline infusion (Fig. 3c,d and Supplementary  Fig. 3a,b) , but it reversed the ability of metformin to alter glucose metabolism (Fig. 3c,d and Supplementary Fig. 3a) . Afferent vagal signaling synapses at the level of the NTS and activation of NMDA receptors in the NTS mediate gut nutrient sensing to lower HGP 15 . Here we saw that direct infusion of MK-801, as compared to saline, into the NTS did not by itself affect glucose metabolism (Fig. 3e,f and Supplementary Fig. 3c,d ), but it did attenuate the higher glucose infusion rate (Fig. 3e) and lower HGP ( Fig. 3f and Supplementary  Fig. 3c ) caused by metformin infusion without affecting glucose uptake (Supplementary Fig. 3d) . We repeated these studies in rats that underwent hepatic vagal branch vagotomy (HVAG), thereby eliminating the neurocommunication between the brain and liver. HVAG abolished the ability of duodenal metformin to alter glucose metabolism in rats (Fig. 3g,h and Supplementary Fig. 3e,f) as it did in sham-operated rats, but HVAG alone did not affect glucose metabolism. Thus, duodenal metformin activates a gut-brain-liver axis to inhibit HGP. To determine the therapeutic potential of metformin action in the duodenum, we infused metformin intraduodenally in rat models of obesity and type 2 diabetes. First we tested the effects of preabsorptive metformin in a chronic (28 d) hyperphagic HFD-fed obese rat model (Fig. 4a) , which is characterized by increased fat mass and insulin resistance (data not shown). Compared to saline, intraduodenal metformin still resulted in a higher glucose infusion rate (Fig. 4b) and lower HGP (Fig. 4c and Supplementary Fig. 4a ) without affecting glucose uptake (Supplementary Fig. 4b ) in this obese rat model. For the type 2 diabetic model, we injected rats with nicotinamide (NA) and streptozotocin (STZ) and fed them an HFD for 5-6 d, inducing mild hyperglycemia and increased HGP (Supplementary Fig. 4c,d ), but not insulin deficiency, as described 29 (data not shown). In unclamped conditions, NA-STZ-treated, HFD-fed type 2 diabetic rats given a 50 min duodenal infusion of metformin exhibited lower plasma glucose levels (Fig. 4d) and lower HGP (Fig. 4e) compared to rats given saline infusion. Thus, preabsorptive duodenal metformin is sufficient to lower plasma glucose levels and HGP in rat models of obesity and diabetes.
Last, to assess the contribution of duodenal Ampk in the acute glucose-lowering effect of metformin in an unclamped setting, we administered an intragastric bolus dose of metformin (200 mg/kg) to NA-STZ-treated, HFD-fed type 2 diabetic rats that had received an intraduodenal injection of either Ad-dn-Ampk or Ad-GFP (as described above) (Fig. 4f) . After 60 min, metformin decreased plasma glucose levels, as compared to baseline, in Ad-GFP-treated rats but not in Ad-dn-Ampk-treated rats (Fig. 4g) . By 180 min after treatment, although metformin decreased plasma glucose levels in both groups, they were still higher in the Ad-dn-Ampk treated rats than in the Ad-GFP-treated rats (Fig. 4g) . In line with this, suppression of plasma glucose levels was greater in Ad-GFP-treated rats than in Ad-dn-Ampk-treated rats, and this difference started as early as 30 min after gastric bolus and was still present 180 min later (Fig. 4h) . Thus, activation of intestinal Ampk contributes to the rapid, overall ability of metformin to lower plasma glucose levels in diabetes.
Metformin is currently the most widely prescribed treatment for type 2 diabetes 30 . Recently, metformin and other biguanides have been documented to reduce cancer risk 31, 32 and increase lifespan in rodents 33 , which furthers the need and the urgency to elucidate their modes of action. Adding to and complementing the known direct hepatic actions of metformin [1] [2] [3] [4] [5] [6] , we demonstrate that preabsorptive metformin remotely (indirectly and acutely) lowers HGP via activation of duodenal Ampk and a neuronal network.
Our findings do not rule out the possibility that metformin directly inhibits HGP through the aforementioned mechanisms 1,3-6 , as metformin still sufficiently lowers plasma glucose levels in rats 90 min after an intragastric bolus regardless of whether duodenal Ampk sensing is disrupted. However, we discovered here that metformin initially (within the first 60 min) reduces plasma glucose levels only in rats with intact duodenal Ampk signaling. Furthermore, the initial drop in glucose levels via duodenal Ampk activation has a major and sustained contribution to the overall suppression of plasma glucose levels, highlighting the fact that an intestinal metformin-Ampkdependent pathway that lowers blood glucose levels may have been overlooked by previous studies.
For example, it is possible that intestinal Ampk mediates the ability of metformin to rapidly (as early as 20 min after administration) lower blood glucose levels in mice lacking hepatic Ampk, an ability that was originally hypothesized to be due to Ampk-independent decreases in the hepatic energy state 1 . Furthermore, although a rapid reduction (60 min after metformin treatment) in plasma glucose levels mirrors a change in plasma lactate/pyruvate ratios following intravenous (i.v.) metformin administration 3 , there is no evidence that metformin acts directly in the liver to alter hepatocellular redox state (that is, an experiment that negates hepatic uptake of metformin was not performed in vivo). In fact, studies have shown that metformin accumulates mostly in the gastrointestinal tract after only 30 min of i.v. metformin administration 34 . In light of these findings, we propose that the acute glucose-lowering effect of metformin is largely mediated by intestinal mechanisms, whereas the relatively long-term or chronic effects of metformin treatment are likely mediated by a direct hepatic mechanism. For example, a recent report documented that the lipid-lowering and insulin-sensitizing effects of chronic metformin treatment were dependent upon the ability of metformin to increase hepatic Ampk activity and inhibit Acc 2 .
Preabsorptive metformin's action is dependent on duodenal Glp1r, consistent with the view that metformin increases Glp-1 levels 20, 22 .
Although this remains to be tested, it is likely that metformin acts directly on enteroendocrine L cells localized in the duodenum 35 to stimulate the local release of Glp-1. In light of the necessary upstream role of duodenal Ampk and the fact that AICAR, an Ampk agonist, also increases circulating Glp-1 levels 20, 36 , future studies are needed to elucidate the underlying mechanistic links of Ampk to Glp-1 release.
In summary, we demonstrate that metformin activates a previously unappreciated duodenal Ampk-Glp-1R-Pka-dependent neuronal pathway to lower HGP and plasma glucose levels in rat models of obesity and diabetes, and that activation of duodenal Ampk substantially contributes to the overall, acute glucose-lowering effect of metformin. Our findings lay the groundwork for the potential development of specific gut-targeted treatments that could activate intestinal energy sensor proteins, such as Ampk, to lower HGP and improve glycemia in individuals with diabetes and obesity.
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Methods and any associated references are available in the online version of the paper. 37 and hepatic insulin resistance 38 . Rats that did not overeat were excluded from the study.
week HFD-induced model of insulin-resistant obesity.
We placed rats on lard-oil-enriched HFD for 28 d. We performed duodenal and vascular cannulations on day 24 after placement on the HFD and performed the pancreatic (basal insulin)-euglycemic clamp experiment on day 28 after recovery from surgical procedures.
NA-STZ-HFD-induced model of type 2 diabetes.
We treated rats with a single injection of nicotinamide (170 mg kg −1 i.p.) followed 15 min later by a single injection of streptozotocin (65 mg kg −1 ). 4-5 d later, we performed duodenal and vascular cannulations and placed rats on a lard-oil enriched HFD (described above) to induce insulin resistance. Rats that were extremely hyperglycemic (blood glucose level >300 mg dl −1 ) were excluded from the study. 5-6 d after surgery, we subjected rats to the basal [3-3 H]glucose infusion protocol.
Animal surgery. We performed surgeries 4 d prior to the clamp experiments. We placed a duodenal catheter 2 cm distal to the pyloric sphincter for infusion purposes, while carotid artery and jugular vein cannulations were performed for infusion and sampling during the clamp and non-clamp in vivo experiments. We flushed the duodenal catheter daily with saline to ensure potency. A subgroup of rats received hepatic portal vein cannulations as described 18 . A separate group of rats received hepatic vagotomy procedures immediately prior to duodenal cannulations 15 . A subgroup of rats underwent stereotaxic surgery 6 d prior to duodenal and vascular surgeries. We stereotactically implanted a 26-gauge bilateral guide cannula made of stainless steel into the NTS (0.0 mm on occipital crest, 0.4 mm lateral to midline, 7.9 mm below skull surface) as previously described 39 . We monitored rats for recovery from surgery by measuring daily food intake and body weight. Rats that did not fully recover were excluded from the study. Rats were randomly designated into groups prior to experiment and no blinding was done during the experimental procedures described below.
Virus injection.
A randomized subset of rats also received a duodenal adenovirus injection prior to the insertion of the duodenal cannula and artery and vein cannulations, as described previously 40 . Briefly, we tied off a 4 cm section of the proximal duodenum (1 cm distal to the pyloric sphincter) with two silk ligatures to prevent inflow of intestinal fluid and outflow of the virus, flushed the intestinal section with saline, and administered 0.2 ml of the adenovirus encoding either the dominant-negative Ampk protein (Ad-dn-Ampk (D 157 A); 3.1 × 10 -9 PFU ml −1 ) or green fluorescent protein (Ad-GFP, 1.4 × 10 9 PFU ml −1 ) described earlier 41 via a 23-gauge needle directly into the duodenal lumen. After 20 min, we inserted a duodenal catheter into the site of the virus injection and vascular cannulations were performed as described above.
Pancreatic (basal insulin)-euglycemic clamp procedures. The night prior to the clamp, we restricted rats to 103 kcal of the HFD. The clamp procedure was 200 min in duration and performed in unrestrained rats in vivo. At the onset of the experiment (t = 0 min), a primed intravenous infusion of [3-3 H]glucose (PerkinElmer; 40 µCi bolus; 0.4 µCi min −1 ) was started and continued throughout the experiment (t = 200 min) in order to measure glucose kinetics using the tracer-dilution methodology. A subset of rats received NTS infusions, in which saline and MK-801 infusions were started at t = 90 min and continued throughout the clamp (t = 200 min) experiment. At t = 90 min, the clamp was started, in which somatostatin (3 µg kg −1 min −1 ) was infused intravenously to inhibit endogenous insulin and glucagon secretion and an insulin infusion was simultaneously administered at a dose of 1.2 mU kg −1 min −1 for the pancreatic (basal insulin)-euglycemic clamp. Additionally, a variable 25% glucose infusion was started at t = 90 min and periodically adjusted to maintain euglycemia (from t = 120 to t = 200 min). At t = 150 min, the intraduodenal treatment (0.01 ml min −1 ) of treatments outlined below was started and continued throughout the experiment (t = 200 min). Plasma samples were obtained every 10 min to determine the specific activity of [3-3 H]glucose and measure insulin levels. At the end of the experiments, rats were anesthetized and tissue samples were collected, immediately flash frozen and stored at −80 °C until use.
Basal [3-3 H]glucose infusion protocol (non-clamp conditions).
The night prior to the infusion studies, we restricted rats to 103 kcal of the HFD. These studies were performed in the diabetic model described above. The infusion experiment was 140 min in duration, and performed in unrestrained rats in vivo. A primed continuous infusion of [3-3 H] glucose was started at t = 0 min and continued until t = 140 min. Duodenal infusions of treatments outlined below were started at t = 90 min and continued throughout the experiment. Plasma samples were collected every 10 min from t = 60 min to t = 90 min and from t = 100 min and t = 140 min to determine plasma glucose levels and [3-3 H]glucose specific activity.
Treatments. The following treatments were infused into the lumen of the duodenum during the in vivo experiments at a rate of 0.01 ml min −1 for 50 min: saline; metformin (200 mg kg −1 or 50 mg kg −1 , Sigma-Aldrich, St. Louis, MO, USA); A769662 (3 mg kg −1 , Tocris Bioscience, Bristol, UK); compound C (100 µM, Millipore); MK-329 (0.08 mg ml −1 , Tocris Bioscience); vi) Exendin-9 (15 µg ml −1 , Tocris Bioscience); Rp-Camps (12 µM, Tocris Bioscience); and tetracaine (0.01 mg min −1 , Sigma-Aldrich). The 200 mg kg −1 metformin dose selected was modified from previous studies utilizing gavage of metformin at 250 mg kg −1 (refs. 1,4), accounting for the fact that after 50 min, not all of that dose would have emptied into the duodenum. The 50 mg kg −1 dose of metformin was chosen based on the fact that a 50 mg kg −1 intragastric gavage of metformin in rats results in plasma metformin concentrations (< 20 µM) 42 similar to those observed following therapeutic oral treatments of metformin in humans (~3-23 µM) 43 . The following treatments were infused into the NTS during the pancreatic (basal-insulin)-euglycemic clamp experiments at a rate of 0.006 µl min −1 : saline and MK-801 (0.03 ng min −1 , Sigma-Aldrich) 15 .
Intragastric bolus protocol.
A separate group of NA-STZ-treated, HFD-fed rats were subject to the viral duodenal infection, fitted with a gastric cannula in the fundic region of the stomach and switched to an HFD for 5 d. The night prior to the experiment, we restricted rats to 103 kcal of HFD. For the experiment, we infused a bolus of metformin (200 mg per kg of body weight; t = 0). Plasma samples were collected at t = −5, 0, 5, 15, 30, 60, 90, 120, 150 and 180 min.
Tissue collection and preparation for western blotting. Immediately following termination of the experiments, the duodenal mucosa was separated from the duodenal smooth muscle after removal from anesthetized rats, and the liver was freeze clamped using steel tongs pre-cooled in liquid nitrogen. The tissues were lysed on ice with a handheld homogenizer in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Nonidet P40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 µM dithiothreitol (DTT) and 2× protease inhibitor cocktail (Roche). The protein concentration of homogenized tissues was determined using the Pierce 660 nm protein assay (Thermo Scientific).
Cell culture. We infected HEK293 cells with either Ad-GFP (50 µl in 10 ml medium) or Ad-dn-Ampk (25 µL) described above, and the following day treated the cells with either saline or metformin (10 mM; Sigma-Aldrich) for 6 h.
